This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hong, Y. Articles by Lin, D. Search for Related Content PubMed PubMed Citation Articles by Hong, Y. Articles by Lin, D.

The Role of P53 and MDM2 Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma

¹ State Key Laboratory of Molecular Oncology and ² Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Requests for reprints: Dongxin Lin, Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences, Beijing 100021, China. Fax: 86-10-6772-2460; E-mail: dlin{at}public.bta.net.cn. Zhihua Liu, State Key Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Beijing 10021, China. Fax: 86-10-6772-3789; E-mail: liuzh{at}pubem.cicams.ac.cn

The tumor suppressor P53 pathway plays a crucial role in preventing carcinogenesis and genetic variations of this pathway may be associated with cancer susceptibility. We tested this hypothesis by examining the contribution of functional polymorphisms in P53 and MDM2 to risk of esophageal squamous cell carcinoma (ESCC). DNA from 758 ESCC patients and 1,420 controls were genotyped for P53 codon 72Arg>Pro and MDM2 309T>G polymorphisms. Odds ratios (OR) and 95% confidence intervals (CI) of ESCC were estimated by logistic regression. We observed an increased risk of ESCC associated with the P53 Pro/Pro (OR, 1.83; 95% CI, 1.43-2.35; P < 0.001) or MDM2 GG (OR, 1.49; 95% CI, 1.16-1.91; P = 0.002) genotype, compared with the P53 Arg/Arg or MDM2 TT genotype, respectively. Interaction between these P53 and MDM2 polymorphisms increased risk of ESCC in a multiplicative manner, with the OR being 3.10 (95% CI, 2.07-4.69) for subjects carrying both P53 Pro/Pro and MDM2 GG genotypes. Significant interactions were observed between these polymorphisms and smoking, with risk being the highest (OR, 5.29; 95% CI, 2.91-9.61) in smokers having both P53 Pro/Pro and MDM2 GG genotypes. The MDM2 GG genotype was also associated with risk of developing poorly differentiated and advanced ESCC compared with the GT or TT genotype (OR for high-grade and stages III-IV versus low-grade and stages I-II = 1.60; 95% CI, 1.00-2.64; P = 0.049). The P53 and MDM2 polymorphisms may be genetic determinants for the development of ESCC.

This article has been cited by other articles:

				N. A. Ellis, D. Huo, O. Yildiz, L. J. Worrillow, M. Banerjee, M. M. Le Beau, R. A. Larson, J. M. Allan, and K. Onel MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility Blood, August 1, 2008; 112(3): 741 - 749. [Abstract] [Full Text] [PDF]

				Y. J. Yoon, H. Y. Chang, S. H. Ahn, J. K. Kim, Y. K. Park, D. R. Kang, J. Y. Park, S. M. Myoung, D. Y. Kim, C. Y. Chon, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection Carcinogenesis, June 1, 2008; 29(6): 1192 - 1196. [Abstract] [Full Text] [PDF]

				S. Cattelani, R. Defferrari, S. Marsilio, R. Bussolari, O. Candini, F. Corradini, G. Ferrari-Amorotti, C. Guerzoni, L. Pecorari, C. Menin, et al. Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients Clin. Cancer Res., June 1, 2008; 14(11): 3248 - 3253. [Abstract] [Full Text] [PDF]

				F. Bartel, J. Jung, A. Bohnke, E. Gradhand, K. Zeng, C. Thomssen, and S. Hauptmann Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival Clin. Cancer Res., January 1, 2008; 14(1): 89 - 96. [Abstract] [Full Text] [PDF]

				Z. Hu, G. Jin, L. Wang, F. Chen, X. Wang, and H. Shen MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2717 - 2723. [Abstract] [Full Text] [PDF]

				S. Wilkening, J. L. Bermejo, and K. Hemminki MDM2 SNP309 and cancer risk: a combined analysis Carcinogenesis, November 1, 2007; 28(11): 2262 - 2267. [Abstract] [Full Text] [PDF]

				M. Yang, Y. Guo, X. Zhang, X. Miao, W. Tan, T. Sun, D. Zhao, D. Yu, J. Liu, and D. Lin Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer Carcinogenesis, September 1, 2007; 28(9): 1996 - 2001. [Abstract] [Full Text] [PDF]

				P. Rajaraman, S. S. Wang, N. Rothman, M. M. Brown, P. M. Black, H. A. Fine, J. S. Loeffler, R. G. Selker, W. R. Shapiro, S. J. Chanock, et al. Polymorphisms in Apoptosis and Cell Cycle Control Genes and Risk of Brain Tumors in Adults Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1655 - 1661. [Abstract] [Full Text] [PDF]

				H. Hirata, Y. Hinoda, N. Kikuno, K. Kawamoto, Y. Suehiro, Y. Tanaka, and R. Dahiya MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma Clin. Cancer Res., July 15, 2007; 13(14): 4123 - 4129. [Abstract] [Full Text] [PDF]

				J. Lu, L.-E Wang, P. Xiong, E. M. Sturgis, M. R. Spitz, and Q. Wei 172G>T variant in the 5' untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant Carcinogenesis, May 1, 2007; 28(5): 988 - 994. [Abstract] [Full Text] [PDF]

				G. Zhou, Y. Zhai, Y. Cui, X. Zhang, X. Dong, H. Yang, Y. He, K. Yao, H. Zhang, L. Zhi, et al. MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese Population Clin. Cancer Res., May 1, 2007; 13(9): 2627 - 2633. [Abstract] [Full Text] [PDF]

				W. Hu, Z. Feng, L. Ma, J. Wagner, J. J. Rice, G. Stolovitzky, and A. J. Levine A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells Cancer Res., March 15, 2007; 67(6): 2757 - 2765. [Abstract] [Full Text] [PDF]

				G. S. Atwal, G. L. Bond, S. Metsuyanim, M. Papa, E. Friedman, T. Distelman-Menachem, E. Ben Asher, D. Lancet, D. A. Ross, J. Sninsky, et al. Haplotype structure and selection of the MDM2 oncogene in humans PNAS, March 13, 2007; 104(11): 4524 - 4529. [Abstract] [Full Text] [PDF]

				L. E. Mechanic, E. D. Bowman, J. A. Welsh, M. A. Khan, N. Hagiwara, L. Enewold, P. G. Shields, L. Burdette, S. Chanock, and C. C. Harris Common Genetic Variation in TP53 Is Associated with Lung Cancer Risk and Prognosis in African Americans and Somatic Mutations in Lung Tumors Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 214 - 222. [Abstract] [Full Text] [PDF]

				S. R. Pine, L. E. Mechanic, E. D. Bowman, J. A. Welsh, S. C. Chanock, P. G. Shields, and C. C. Harris MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1559 - 1561. [Abstract] [Full Text] [PDF]

				G. L. Bond, K. M. Hirshfield, T. Kirchhoff, G. Alexe, E. E. Bond, H. Robins, F. Bartel, H. Taubert, P. Wuerl, W. Hait, et al. MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Res., May 15, 2006; 66(10): 5104 - 5110. [Abstract] [Full Text] [PDF]

				Y. Li, X. Zhang, G. Huang, X. Miao, L. Guo, D. Lin, and S.-H. Lu Identification of a novel polymorphism Arg290Gln of esophageal cancer related gene 1 (ECRG1) and its related risk to esophageal squamous cell carcinoma Carcinogenesis, April 1, 2006; 27(4): 798 - 802. [Abstract] [Full Text] [PDF]